S&P lowers outlook for Jubilant Pharma to negative, sees weak performance

Standard and Poor’s (S&P) has lowered outlook on Jubilant Pharma Ltd from “stable” to “negative” on likely weaker operating performance by the drugmaker.

The rating agency affirmed the long-term issuer credit rating at “BB”. Jubilant’s operating performance could remain weak over the next 12 months due to regulatory issues in its generics business and the loss of one-time development and manufacturing contracts related to Covid-19.

The negative outlook reflects the likelihood of a downgrade if the group’s EBITDA margins remain below 20 per cent and debt-to-EBITDA ratio stays above 2x without signs of improving toward about 2x beyond the next 12 months.

Singapore-based Jubilant Pharma has presence in the niche specialty (radiopharma and allergy therapy products) pharmaceuticals, generics manufacturing, and CDMO of API and sterile injectables and non-sterile products. Jubilant Pharma is a 100 per cent-owned subsidiary of India-listed Jubilant Pharmova Ltd.

The group’s EBITDA will be lower by 10-12 per cent in fiscal 2023 (year ending March 31, 2023), compared to fiscal 2021 levels, despite an about 15% year-on-year growth. This is primarily because of the weaker performance of the group’s generics and contract development and manufacturing operations (CDMO) business segments.

In July 2021, the U.S. Food and Drug Administration (USFDA) restricted imports from the group’s solid dosage formulations facility in Roorkee, India. The CDMO business is also losing revenue as one-time contracts for Covid-19-related drugs and vaccines start tapering off. The generics and the CDMO segments accounted for about half of the group revenues in fiscal 2021.

The issues at the group’s Roorkee plant are expected to be resolved by the end of fiscal 2023 without further significant drag on earnings. Moreover, Jubilant Pharma is working on replacing its one-off Covid-19-related CDMO business with more stable products. The group’s EBITDA should recover to fiscal 2021 levels in fiscal 2024.

Not recovering from its current operational weakness is a key rating risk for Jubilant Pharma. The expectation of an improvement in earnings by the end of fiscal 2023, compared to fiscal 2022, hinges on the good recovery of the radiopharmaceuticals business, S&P said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor